

An Information Service of the Division of Health Benefits

North Carolina Medicaid Pharmacy Newsletter

Number 338

February 2022

In This Issue...

Billing information for Continuous Glucose Monitoring for CPPs

SPECIAL BULLETIN COVID-19 #216: Pharmacies Will Cover Oral Tablets (Paxlovid and Molnupiravir)

SPECIAL BULLETIN COVID-19 #217: Third Dose of Pfizer-BioN Tech Vaccine for Children Ages 5-11

Ozobax and Qdolo Update

Over-the-Counter COVID-19 Tests for Home Use

Preferred Brands with Non-Preferred Generics on the Preferred Drug List (PDL)

72-Hour Emergency Supply Available for Pharmacy Prior Authorization Drugs

Checkwrite Schedule for February 2022

Published by GDIT, fiscal agent for the North Carolina Medicaid Program 800-688-6696

Attention: Clinical Pharmacist Practitioners Billing Information for Continuous Glucose Monitoring for CPPs

Effective Feb. 1, 2022, Clinical Pharmacist Practitioner (CPP) taxonomy code 1835P0018X will be allowed to bill and be reimbursed for:

- CPT code 95249 Ambulatory continuous glucose monitoring (CGM) of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; patient-provided equipment, sensor placement, hook-up, calibration of monitor, patient training and printout of recording. Reimbursement rate at \$44.80.
- CPT code 95250 Ambulatory CGM of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; physician or other qualified health care professional (office) provided equipment, sensor placement, hook-up, calibration of monitor, patient training, removal of sensor and printout of recording. Reimbursement rate at \$122.63.

Both codes are used for the technical component of CGM, and covers patient training, glucose sensor placement, monitor calibration, use of a transmitter, removal of sensor and downloading of data.

ICD-10 Diagnosis Codes must accompany the claim:

E10.649 Type 1 diabetes mellitus with hypoglycemia without coma
E10.65 Type 1 diabetes mellitus with hyperglycemia
E10.69 Type 1 diabetes mellitus with other specified complication
E10.8 Type 1 diabetes mellitus with unspecified complications
E10.9 Type 1 diabetes mellitus with other specified complications
E11.649 Type 2 diabetes mellitus with hypoglycemia without coma
E11.65 Type 2 diabetes mellitus with hyperglycemia
E11.69 Type 2 diabetes mellitus with other specified complication
E11.8 Type 2 diabetes mellitus with other specified complications
E11.9 Type 2 diabetes mellitus with unspecified complications
E13.8 Other diabetes mellitus with unspecified complications
E13.9 Other specified diabetes mellitus without complication

The <u>CPP Fee schedule</u> lists the reimbursement information for CPPs.

SPECIAL BULLETIN COVID-19 #216: Pharmacies Will Cover Oral Tablets (Paxlovid and Molnupiravir)

Oral tablets covered for those in a home setting

Effective Jan. 1, 2022, NC Medicaid-enrolled pharmacies may bill for FDA/EUA-approved COVID-19 oral tablets (Paxlovid and/or Molnupiravir) dispensed for use to NC Medicaid beneficiaries in a home setting, with a prescription issued by an NC Medicaid-enrolled provider (refer to beneficiaries' managed care plan for guidance on the specific plan's implementation date).

- NC Medicaid will cover one claim per date of service per beneficiary.
- The claim must have a prescribing provider.
- Pharmacies must follow the NCPDP standard and use the NDC found on the package.

- Pharmacies will be NOT be reimbursed for the ingredient cost since the drugs are federally provided at no cost.
- Dispensing fee will apply.
- Copayment will not apply.

For more information, see FDA letters:

- Paxlovid EUA
- <u>Molnupiravir EUA</u>

SPECIAL BULLETIN COVID-19 #217: Third Dose of Pfizer-BioN Tech Vaccine for Children Ages 5-11 *Certain immunocompromised children will qualify*

On Jan. 3, 2022, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for a third dose in the primary series for certain immunocompromised children ages 5 through 11. This includes children who have undergone solid organ transplantation or who have been diagnosed with conditions which are considered to have an equivalent level of immunocompromise. Children ages 5 through 11 who are fully vaccinated and are not immunocompromised do not need a third dose at this time.

As of Jan. 3, 2022, Medicaid and NC Health Choice will cover a third dose of the Pfizer-BioNTech COVID-19 Vaccine primary series for immunocompromised children ages 5 through 11 for all vaccinating providers.

The new vaccine administration code assigned to the third dose of Pfizer's pediatric COVID-19 vaccine is:

| 91307 | SARS-CoV-2 vaccine product (tris-sucrose formulation) administered by intramuscular injection to prevent the patient from contracting COVID-19. 10 mcg/0.2 mL |
|-------|---|
| 0073A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose |

All other aspects of claims billing still apply (see <u>COVID-19 Bulletin #196</u> for details). If you have any questions about product-specific information, please contact the Immunization Branch help desk at 877-873-6247 and press option 6.

Ozobax and Qdolo Update

NC Medicaid has received information that as of Jan. 1, 2022 Ozobax (baclofen) Solution and Qdolo (tramadol) Solution are no longer rebate eligible medications. Per <u>NC Medicaid Clinical</u> <u>Coverage Policy 9</u>, only medications that are included in the federal Medicaid Drug Rebate Program (MDRP) are eligible for coverage unless specifically added via a Policy and State Plan Amendment update. Therefore, these medications are no longer covered in the NC Medicaid and NC Health Choice programs. As a reminder, NC Medicaid does cover compounded medications when providers use commercially available, rebate-eligible products in the compound. NC Medicaid does not cover compounded medications when a bulk powder product is used. Please refer to Clinical Coverage Policy 9 (see link above) for more information.

Over-the-Counter COVID-19 Tests for Home Use

Effective Jan. 10, 2022, NC Medicaid enrolled pharmacy providers may bill POS for FDA approved OTC COVID-19 tests dispensed for use by NC Medicaid beneficiaries in a home setting. The test can be dispensed with or without a prescription issued by an active NC Medicaid enrolled provider. The implementation date for POS claims submission is Jan. 10, 2022, for NC Medicaid Direct. Refer to the managed care plan of the beneficiary for implementation date guidance.

NC Medicaid will cover one kit per claim per date of service. A maximum of eight tests is allowed every rolling 30 days. The eight total tests could be mixed and matched between one-test kits or two-test kits to get a total of eight tests.

A <u>State Standing Order</u> has been issued for the OTC COVID 19 test for home use.

Another option is to submit the claim using the pharmacy NPI unless the test is prescribed by a Medicaid enrolled provider.

Pharmacies must follow the NCPDP standard and use the NDC found on the package. Reimbursement is at a NDC specific SMAC. Copayment will not apply.

| Test Name | NDC | # Tests in | Billing | SMAC |
|----------------------------|-----------|------------|---------|------------------------|
| | | Kit | Unit | |
| Quickvue At-Home Covid-19 | 146130339 | | | \$14.50/test; \$29.00/ |
| Test | 72 | 2 | 2 | kit |
| Inteliswab Covid-19 Rapid | 083370001 | | | \$14.50/test; |
| Test | 58 | 2 | 2 | \$29.00/kit |
| IHEALTH Covid-19 AG | 563620005 | | | \$10.50/test; |
| Rapid Test | 89 | 2 | 2 | \$21.00/kit |
| Flowflex Covid-19 AG Home | 826070660 | | | \$12.49/test; |
| Test | 27 | 2 | 2 | \$24.98/kit |
| Flowflex Covid-19 AG Home | 826070660 | | | \$14.99/test; |
| Test | 26 | 1 | 1 | \$14.99/kit |
| | 569640000 | | | \$37.54/test; |
| Ellume Covid-19 Home Test | 00 | 1 | 1 | \$37.54/kit |
| Carestart Covid-19 AG Home | 500100224 | | | \$16.23/test; |
| Test | 31 | 2 | 2 | \$32.46/kit |
| Binaxnow Covid-19 AG Self | 118770011 | | | \$13.83/test; |
| Test | 40 | 2 | 2 | \$27.66/kit |
| Pixel Covid-19 Home | 000420222 | | | 129.99/test; |
| Collection Kit | 24 | 1 | 1 | \$129.99/kit |
| Lucira Check-It Covid-19 | 100550970 | | | \$80.00/test; |
| Test | 04 | 1 | 1 | \$\$80.00/kit |
| Everlywell Covid-19 Home | 510440008 | | | \$114.00/test; |
| Collection Kit | 42 | 1 | 1 | \$114.00/kit |

Covered test kits with the SMAC are listed below.

Preferred Brands with Non-Preferred Generics on the Preferred Drug List (PDL) *Current as of Jan. 31, 2022*

E.

| Brand Name | Generic Name | | |
|------------------------------|--|--|--|
| Actiq 1200 mcg Lozenges | Fentanyl Citrate 1200 mcg Lozenges | | |
| Actiq 1600 mcg Lozenges | Fentanyl Citrate 1600 mcg Lozenges | | |
| Actiq 200 mcg Lozenges | Fentanyl Citrate 200 mcg Lozenges | | |
| Actiq 400 mcg Lozenges | Fentanyl Citrate 400 mcg Lozenges | | |
| Actiq 600 mcg Lozenges | Fentanyl Citrate 600 mcg Lozenges | | |
| Actiq 800 mcg Lozenges | Fentanyl Citrate 800 mcg Lozenges | | |
| Adderall XR 10 mg | Amphetamine Salt Combo ER 10 mg | | |
| Adderall XR 15 mg | Amphetamine Salt Combo ER 15 mg | | |
| Adderall XR 20 mg | Amphetamine Salt Combo ER 20 mg | | |
| Adderall XR 25 mg | Amphetamine Salt Combo ER 25 mg | | |
| Adderall XR 30 mg | Amphetamine Salt Combo ER 30 mg | | |
| Adderall XR 5 mg | Amphetamine Salt Combo ER 5 mg | | |
| Advair 100-50 Diskus | Fluticasone-Salmeterol 100-50 | | |
| Advair 250-50 Diskus | Fluticasone-Salmeterol 250-50 | | |
| Advair 500-50 Diskus | Fluticasone-Salmeterol 500-50 | | |
| Alphagan P 0.15% Drops | Brimonidine P 0.15% Drops | | |
| Amitiza 8 mcg Capsule | Lubiprostone 8 mcg Capsule | | |
| Amitiza 24 mcg Capsule | Lubiprostone 24 mcg Capsule | | |
| Androgel Pump | Testosterone Gel Pump | | |
| Apriso ER 0.375 Gram Capsule | Mesalamine 0.375 mg Capsule | | |
| Aptensio XR 10mg Capsule | Methylphenidate ER 10 mg Capsule | | |
| Aptensio XR 15mg Capsule | Methylphenidate ER 15 mg Capsule | | |
| Aptensio XR 20mg Capsule | Methylphenidate ER 20 mg Capsule | | |
| Aptensio XR 30mg Capsule | Methylphenidate ER 30 mg Capsule | | |
| Aptensio XR 40mg Capsule | Methylphenidate ER 40 mg Capsule | | |
| Aptensio XR 50mg Capsule | Methylphenidate ER 50 mg Capsule | | |
| Aptensio XR 60mg Capsule | Methylphenidate ER 60 mg Capsule | | |
| Bethkis 300 mg/4 ml Ampule | Tobramycin Solution 300 mg/4 ml Ampule | | |
| Butrans 10 mcg/hr Patch | Buprenorphine 10 mcg/hr Patch | | |
| Butrans 15 mcg/hr Patch | Buprenorphine 15 mcg/hr Patch | | |
| Butrans 20 mcg/hr Patch | Buprenorphine 20 mcg/hr Patch | | |
| Butrans 5 mcg/hr Patch | Buprenorphine 5 mcg/hr Patch | | |
| Butrans 7.5 mcg/hr Patch | Buprenorphine 7.5 mcg/hr Patch | | |
| Catapres-TTS 1 Patch | Clonidine 0.1 mg/day Patch | | |
| Catapres-TTS 2 Patch | Clonidine 0.2 mg/day Patch | | |
| Catapres-TTS 3 Patch | Clonidine 0.3 mg/day Patch | | |
| Canasa 1,000 mg Suppository | Mesalamine 1,000 mg Suppository | | |
| Cipro 10% Suspension | Ciprofloxacin 500 mg/5 ml Suspension | | |

| Ciprodex Otic SuspensionCiprofloxatClobex 0.005% ShampooClobetasolCombigan 0.2%-0.5% Eye DropsBrimonidirConcerta 18 mg tabMethylphetConcerta 27 mg tabMethylphetConcerta 36 mg tabMethylphetConcerta 54 mg tabMethylphetCopaxone 20 mg/ml SyrGlatiramerCopaxone 40 mg/ml SyrGlatiramerDerma-Smoothe-FS Body OilFluocinoloDerma-Smoothe-FS Scalp OilFluocinolo | cin 250 mg/5 ml Suspension cin/Dexamethasone Suspension 0.005% Shampoo ne-Timolol 0.2%-0.5% nidate ER 18 mg nidate ER 27 mg nidate ER 27 mg nidate ER 36 mg nidate ER 36 mg 20 mg/ml Syr 40 mg/ml Syr ne 0.01% Body Oil ne 0.01% Scalp Oil ne 0.01% Otic Drops |
|---|---|
| Clobex 0.005% ShampooClobetasolCombigan 0.2%-0.5% Eye DropsBrimonidirConcerta 18 mg tabMethylpherConcerta 27 mg tabMethylpherConcerta 36 mg tabMethylpherConcerta 54 mg tabMethylpherCopaxone 20 mg/ml SyrGlatiramerCopaxone 40 mg/ml SyrGlatiramerDerma-Smoothe-FS Body OilFluocinolorDerma-Smoothe-FS Scalp OilFluocinolor | 0.005% Shampoo ae-Timolol 0.2%-0.5% nidate ER 18 mg nidate ER 27 mg nidate ER 27 mg nidate ER 36 mg nidate ER 54 mg 20 mg/ml Syr 40 mg/ml Syr ne 0.01% Body Oil ne 0.01% Scalp Oil ne 0.01% Otic Drops |
| Combigan 0.2%-0.5% Eye DropsBrimonidirConcerta 18 mg tabMethylpherConcerta 27 mg tabMethylpherConcerta 36 mg tabMethylpherConcerta 54 mg tabMethylpherCopaxone 20 mg/ml SyrGlatiramerCopaxone 40 mg/ml SyrGlatiramerDerma-Smoothe-FS Body OilFluocinolorDerma-Smoothe-FS Scalp OilFluocinolor | ne-Timolol 0.2%-0.5% nidate ER 18 mg nidate ER 27 mg nidate ER 36 mg nidate ER 54 mg 20 mg/ml Syr 40 mg/ml Syr ne 0.01% Body Oil ne 0.01% Scalp Oil ne 0.01% Otic Drops |
| Concerta 18 mg tabMethylpherConcerta 27 mg tabMethylpherConcerta 36 mg tabMethylpherConcerta 54 mg tabMethylpherCopaxone 20 mg/ml SyrGlatiramerCopaxone 40 mg/ml SyrGlatiramerDerma-Smoothe-FS Body OilFluocinolorDerma-Smoothe-FS Scalp OilFluocinolor | nidate ER 27 mg nidate ER 36 mg nidate ER 54 mg 20 mg/ml Syr 40 mg/ml Syr ne 0.01% Body Oil ne 0.01% Scalp Oil ne 0.01% Otic Drops |
| Concerta 27 mg tabMethylpherConcerta 36 mg tabMethylpherConcerta 54 mg tabMethylpherCopaxone 20 mg/ml SyrGlatiramerCopaxone 40 mg/ml SyrGlatiramerDerma-Smoothe-FS Body OilFluocinolorDerma-Smoothe-FS Scalp OilFluocinolor | nidate ER 27 mg nidate ER 36 mg nidate ER 54 mg 20 mg/ml Syr 40 mg/ml Syr ne 0.01% Body Oil ne 0.01% Scalp Oil ne 0.01% Otic Drops |
| Concerta 36 mg tabMethylpherConcerta 54 mg tabMethylpherCopaxone 20 mg/ml SyrGlatiramerCopaxone 40 mg/ml SyrGlatiramerDerma-Smoothe-FS Body OilFluocinolorDerma-Smoothe-FS Scalp OilFluocinolor | nidate ER 36 mg nidate ER 54 mg 20 mg/ml Syr 40 mg/ml Syr ne 0.01% Body Oil ne 0.01% Scalp Oil ne 0.01% Otic Drops |
| Concerta 54 mg tabMethylpheCopaxone 20 mg/ml SyrGlatiramerCopaxone 40 mg/ml SyrGlatiramerDerma-Smoothe-FS Body OilFluocinoloDerma-Smoothe-FS Scalp OilFluocinolo | nidate ER 54 mg 20 mg/ml Syr 40 mg/ml Syr ne 0.01% Body Oil ne 0.01% Scalp Oil ne 0.01% Otic Drops |
| Copaxone 20 mg/ml SyrGlatiramerCopaxone 40 mg/ml SyrGlatiramerDerma-Smoothe-FS Body OilFluocinologDerma-Smoothe-FS Scalp OilFluocinolog | 20 mg/ml Syr 40 mg/ml Syr ne 0.01% Body Oil ne 0.01% Scalp Oil ne 0.01% Otic Drops |
| Copaxone 40 mg/ml SyrGlatiramerDerma-Smoothe-FS Body OilFluocinoloDerma-Smoothe-FS Scalp OilFluocinolo | 40 mg/ml Syr ne 0.01% Body Oil ne 0.01% Scalp Oil ne 0.01% Otic Drops |
| Derma-Smoothe-FS Body OilFluocinologyDerma-Smoothe-FS Scalp OilFluocinology | ne 0.01% Body Oil ne 0.01% Scalp Oil ne 0.01% Otic Drops |
| Derma-Smoothe-FS Scalp Oil Fluocinolo | ne 0.01% Scalp Oil ne 0.01% Otic Drops |
| | ne 0.01% Otic Drops |
| · | * |
| Diastat 2.5 mg Pedi System Diazepam | 2.5 mg Rectal Gel System |
| | 20 mg Rectal Gel System |
| 1 | 10 mg Rectal Gel System |
| | e Succinate/Pyridoxine HCL 10-10 DR |
| · · | 0.1% Cream |
| X | 0.3% Gel Pump |
| | ne 0.005% Cream |
| | ate 0.05% Eye Drops |
| | cin Ethyl Succinate 200 mg/5 ml |
| | nus 1% Cream |
| Emend 80 mg Capsule Aprepitant | 80 mg Capsule |
| | Bnzyl Perox 0.3-2.5% |
| | cin Ethyl Succinate 200 mg/5 ml |
| | cin Ethyl Succinate 400 mg/5 ml |
| | ne 13.3 mg/24 hr Patch |
| Exelon 4.6 mg/24 hr Patch Rivastigmi | ne 4.6 mg/24 hr Patch |
| Exelon 9.5 mg/24 hr Patch Rivastigmi | ne 9.5 mg/24 hr Patch |
| | phenidate 10 mg |
| Focalin 2.5 mg Dexmethyl | phenidate 2.5 mg |
| | phenidate 5 mg |
| Focalin XR 10 mg Dexmethyl | phenidate ER 10 mg |
| | phenidate ER 15 mg |
| | phenidate ER 20 mg |
| | phenidate ER 25 mg |
| | phenidate ER 30 mg |
| | phenidate ER 35 mg |
| | phenidate ER 40 mg |
| Č · | phenidate ER 5 mg |
| Gabitril 12 mg Tiagabine | |
| Gabitril 16 mg Tiagabine | - |

| Gabitril 2 mg | Tiagabine 2 mg | | |
|---------------------------------|-------------------------------------|--|--|
| Gabitril 4 mg | Tiagabine 2 mg | | |
| Humalog 100 units/ml Vial | Insulin Lispro 100 units/ml Vial | | |
| Humalog Kwikpen 100 units/ml | Insulin Lispro 100 units/ml | | |
| Humalog Jr Kwikpen 100 units/ml | Insulin Lispro Jr 100 units/ml | | |
| Humalog Kwikpen Mix 75-25 | Insulin Lispro Mix 75-25 | | |
| Kitabis Pak 300 mg/5 ml | Tobramycin Pak 300 mg/5 ml | | |
| Letairis 10 mg Tablet | Ambrisentan 10 mg Tablet | | |
| Letairis 5 mg Tablet | Ambrisentan 5 mg Tablet | | |
| Lialda 1.2 gm Tablet | Mesalamine 1.2 gm Tablet | | |
| Lotemax 0.5% Eye Drops | Loteprednol 0.5% Eye Drops | | |
| Methylin 10 mg/5 ml Solution | Methylphenidate 10 mg/5 ml Solution | | |
| Methylin 5 mg/5 ml Solution | Methylphenidate 5 mg/5 ml Solution | | |
| MetroCream 0.75% Cream | Metronidazole 0.75% Cream | | |
| Metrogel Topical 1% Gel | Metronidazole Topical 1% Gel | | |
| Metrogel Topical 1% Pump | Metronidazole Topical 1% Gel | | |
| Mitigare 0.6 mg capsules | Colchicine 0.6 mg capsules | | |
| Natroba 0.9% Topical Susp | Spinosad 0.9% Topical Susp | | |
| Nexium DR 10 mg Packet | Esomeprazole DR 10 mg Packet | | |
| Nexium DR 20 mg Packet | Esomeprazole DR 20 mg Packet | | |
| Nexium DR 40 mg Packet | Esomeprazole DR 40 mg Packet | | |
| Niaspan ER 1000 mg Tablets | Niacin ER 1000 mg Tablets | | |
| Niaspan ER 500 mg Tablets | Niacin ER 500 mg Tablets | | |
| Niaspan ER 750 mg Tablets | Niacin ER 750 mg Tablets | | |
| Novolog 100 U/ml Cartridge | Insulin Aspart 100 U/ml Cartridge | | |
| Novolog 100 U/ml FlexPen | Insulin Aspart 100 U/ml Pen | | |
| Novolog 100 U Vial | Insulin Aspart 100 U Vial | | |
| Novolog Mix 70-30 FlexPen | Insulin Aspart Pro Mix 70-30 Pen | | |
| Novolog Mix 70-30 Vial | Insulin Aspart Pro Mix 70-30 Vial | | |
| Nuvigil 150 MG Tabs | Armodafinil 150 mg tabs | | |
| Nuvigil 200 MG Tabs | Armodafinil 200 mg tabs | | |
| Nuvigil 250 MG Tabs | Armodafinil 250 mg tabs | | |
| Nuvigil 50 MG Tabs | Armodafinil 50 mg tabs | | |
| ProAir HFA Inhaler | Albuterol HFA Inhaler | | |
| Protopic 0.03% Oint | Tacrolimus 0.03% Oint | | |
| Protopic 0.1% Oint | Tacrolimus 0.1% Oint | | |
| Protonix 40 mg Suspension | Pantoprazole 40 mg Suspension | | |
| Provigil 100 mg | Modafinil 100 mg | | |
| Provigil 200 mg | Modafinil 200 mg | | |
| Pulmicort 0.25 mg/2 ml | Budesonide 0.25 mg/2 ml | | |
| Pulmicort 0.5 mg/2 ml | Budesonide 0.5 mg/2 ml | | |
| Pulmicort 1 mg/2 ml | Budesonide 1.0 mg/2 ml | | |
| Retin-A 0.025% Cream | Tretinoin 0.025% Cream | | |

| Retin-A 0.05% Cream | Tretinoin 0.05% Cream |
|-------------------------------|---|
| Retin-A 0.1% Cream | Tretinoin 0.1% Cream |
| Retin-A Gel 0.01% | Tretinoin Gel 0.01% |
| Retin-A Gel 0.025% | Tretinoin Gel 0.025% |
| Retin-A Micro 0.04% Gel | Tretinoin Micro 0.04% Gel |
| Retin-A Micro 0.1% Gel | Tretinoin Micro 0.1% Gel |
| Retin-A Micro Pump 0.04% Gel | Tretinoin Micro Pump 0.04% Gel |
| Retin-A Micro Pump 0.1% Gel | Tretinoin Micro Pump 0.1% Gel |
| Sabril 500 mg Powder Packet | Vigabatrin 500 mg Powder Packet |
| Saphris 2.5 mg Tab Sublingual | Asenapine 2.5 mg Tablet SL |
| Saphris 5 mg Tab Sublingual | Asenapine 5 mg Tablet SL |
| Saphris 10 mg Tab Sublingual | Asenapine 10 mg Tablet SL |
| Suboxone 12-3 mg Film | Buprenorphine/Naloxone 12-3 mg Film |
| Suboxone 2-0.5 mg Film | Buprenorphine/Naloxone 2-0.5 mg Film |
| Suboxone 4-1 mg Film | Buprenorphine/Naloxone 4-1 mg Film |
| Suboxone 8 mg-2 mg Film | Buprenorphine/Naloxone 8mg-2mg Film |
| Symbicort 160-4.5 mcg Inhaler | Budesonide-Formoterol 160-4.5 mcg Inhaler |
| Symbicort 80-4.5 mcg Inhaler | Budesonide-Formoterol 80-4.5 mcg Inhaler |
| Symbyax 3-25 | Olanzapine-fluoxetine 3-25 |
| Symbyax 6-25 | Olanzapine-fluoxetine 6-25 |
| Tecfidera DR 120 mg Capsule | Dimethyl Fumarate 120 mg Capsule |
| Tecfidera DR 240 mg Capsule | Dimethyl Fumarate 240 mg Capsule |
| Tecfidera Starter Pack | Dimethyl Fumarate Starter Pack |
| Tegretol 100 mg/5 ml Susp | Carbamazepine 100 mg/5 ml Susp |
| Tegretol 200 mg Tab | Carbamazepine 200 mg Tab |
| Tegretol XR 100 mg Tab | Carbamazepine ER 100 mg Tab |
| Tegretol XR 200 mg Tab | Carbamazepine ER 200 mg Tab |
| Tegretol XR 400 mg Tab | Carbamazepine ER 400 mg Tab |
| Tekturna 150 mg Tablet | Aliskiren 150 mg Tablet |
| Tekturna 300 mg Tablet | Aliskiren 300 mg Tablet |
| TobraDex Eye Drops | Tobramycin-Dexamethasone Drops |
| Tracleer 125 mg Tablet | Bosentan 125 mg tablet |
| Tracleer 62.5 mg Tablet | Bosentan 62.5 mg tablet |
| Transderm-Scop 1.5 mg/3 day | Scopolamine 1 mg/3 Day Patch |
| Travatan Z 0.004% Eye Drop | Travoprost 0.004% Eye Drop |
| Vagifem 10 mcg Vaginal Tab | Estradiol 10 mcg Vaginal Insert |
| Zovirax 5% Cream | Acyclovir 5% Cream |
| Zovirax 5% Ointment | Acyclovir 5% Ointment |

As a reminder, if a brand is preferred with a Non-Preferred generic equivalent, "medically necessary" is NOT needed on the face of the prescription in order for the brand product to be covered. Claims for preferred brands with non-preferred generics will be reimbursed with a generic product dispensing fee. Claims for preferred brands with no generic or preferred brands with preferred brands with preferred brands with a brand dispensing fee.

When a PDL class has a preferred brand with a non-preferred generic, providers requesting prior approval for the non-preferred generic should give a clinical reason why the beneficiary cannot use the brand.

72-Hour Emergency Supply Available for Pharmacy Prior Authorization Drugs

Pharmacy providers are encouraged to use the 72-hour emergency supply allowed for drugs requiring prior approval. Federal law requires that this emergency supply be available to Medicaid beneficiaries for drugs requiring prior approval (Social Security Act, Section 1927, <u>42 U.S.C. 1396r-8(d)(5)(B)</u>). Use of this emergency supply will ensure access to medically necessary medications.

The system will bypass the prior approval requirement if an emergency supply is indicated. Use a "3" in the Level of Service field (418-DI) to indicate that the transaction is an emergency fill.

Note: Copayments will apply and only the drug cost will be reimbursed. There is no limit to the number of times the emergency supply can be used.

Checkwrite Schedule for March 2022

| Electronic Cutoff Schedule | Checkwrite Date | |
|----------------------------|------------------------|--|
| Feb. 24, 2022 | March 1, 2022 | |
| March 3, 2022 | March 8, 2022 | |
| March 10, 2022 | March 15, 2022 | |
| March 17, 2022 | March 22, 2022 | |
| March 24, 2022 | March 29, 2022 | |

POS claims must be transmitted and completed by 11:59 p.m. on the day of the electronic cutoff date to be included in the next checkwrite.

The 2022 checkwrite schedules for both NC Medicaid and DMH/DPH/ORH can be found under the Quick Links on the right side of the <u>NCTracks Provider Portal</u> home page.

Angela Smith, PharmD, DHA, BCPS, FACHE Director of Pharmacy, DME/POS, Hearing & Optical, and Ancillary Services Division of Health Benefits, NC Medicaid Sandra Terrell, MS, RN Director of Clinical Programs and Policy Division of Health Benefits N.C. Department of Health and Human Services **Dave Richard** Deputy Secretary for NC Medicaid Division of Health Benefits N.C. Department of Health and Human Services

Shannon Dowler, MD

Chief Medical Officer Division of Health Benefits N.C. Department of Health and Human Services

Rick Paderick, R.Ph.

Pharmacy Director NCTracks GDIT

Lori Landman

Deputy Executive Account Director NCTracks GDIT

Paul Guthery

Executive Account Director NCTracks GDIT